Results 221 to 230 of about 95,044 (332)

Inhibition of phosphodiesterases 1 and 4 prevents myofibroblast transformation in Peyronie's disease

BJU International, Volume 135, Issue 5, Page 810-817, May 2025.
Objectives To investigate which phosphodiesterase (PDE) isoforms are expressed in fibroblasts isolated from the tunica albuginea (TA) of patients with Peyronie's disease (PD), and to measure the potency of PDE inhibitors in preventing transformation of these fibroblasts to profibrotic myofibroblasts.
Sophie L. Harding, Marcus M. Ilg, Stephen A. Bustin, David J. Ralph, Selim Cellek   +4 more
wiley   +1 more source

Epstein–Barr virus and wild p53 in idiopathic pulmonary fibrosis

, 2001
She Lok, James P. Stewart, B. Kelly, P S Hasleton, J. Egan   +4 more
openalex   +1 more source

Does interferon- improve pulmonary function in idiopathic pulmonary fibrosis? [PDF]

, 2003
Antje Prasse, KM Müller, Christian Kurz, Henning Hamm, J. Christian Virchow   +4 more
openalex   +1 more source

Beneficial Impact of Nutritional Therapy on Idiopathic Pulmonary Fibrosis. [PDF]

Cureus
Yamakawa H, Ohta H, Sato S, Matsushima H.   +3 more
europepmc   +1 more source

Natural products targeting tumour angiogenesis

British Journal of Pharmacology, Volume 182, Issue 10, Page 2094-2136, May 2025.
Abstract Tumour angiogenesis is the formation of new blood vessels to support the growth of a tumour. This process is critical for tumour progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumour ...
Xiaohua Lu, Lara Johanna Friedrich, Thomas Efferth   +2 more
wiley   +1 more source

The Therapeutic Effect of Angiotensin II Receptor Antagonist in Idiopathic Pulmonary Fibrosis [PDF]

, 2003
Duck Soo Woo, Won Jong Seol, Sun Young Kyung, Young Hee Lim, Chang Hyeok An, Jeong Woong Park, Sung Hwan Jeong, Jae Woong Lee   +7 more
openalex   +1 more source

The enigma of idiopathic pulmonary fibrosis in upper middle-aged individuals. [PDF]

J Family Med Prim Care
Devalla L, Ghewade B, Wagh P, Alone V.
europepmc   +1 more source

Targeting MLL1/WDR5‐Mediated Epigenetic Regulation Mitigates Peritoneal Fibrosis by Reducing p16INK4a

The FASEB Journal, Volume 39, Issue 8, 30 April 2025.
MLL1/WDR5 inhibition is a promising strategy for treating peritoneal fibrosis by reducing H3K4me3 and p16INK4a expression. Inhibitors MM‐102 and OICR‐9429 suppress fibrosis, inflammation, and senescence in TGF‐β1‐stimulated HPMCs and MGO‐injected mice, improving peritoneal function.
Daisuke Hara, Kensuke Sasaki, Shigehiro Doi, Takeshi Ike, Kazuya Maeda, Maria Yoshida, Akira Takahashi, Yosuke Osaki, Naoki Ishiuchi, Yujiro Maeoka, Toshiki Doi, Takuto Chiba, Ayumu Nakashima, Takao Masaki   +13 more
wiley   +1 more source

Idiopathic Pulmonary Fibrosis: Impact of Angiotensin Converting Enzyme Inhibitors and HMG-CoA Reductase Inhibitor s on Survival [PDF]

, 2003
Hassan F. Nadrous, Eric J. Olson, William W. Douglas, Paul A. Decker, Jay H. Nadrous   +4 more
openalex   +1 more source

The pathogenesis of idiopathic pulmonary fibrosis: from "folies à deux" to "Culprit cell Trio". [PDF]

Pathologica
Chilosi M, Ravaglia C, Doglioni C, Piciucchi S, Stefanizzi L, Poletti V.   +5 more
europepmc   +1 more source